CAR T-cell Therapy for Myositis

How does CAR T-cell therapy work?

CAR T-cell therapy is a revolutionary treatment sometimes called a “living medicine.” Instead of giving a drug that suppresses the immune system, doctors collect your own immune cells and re-engineer them to remove the cells driving the disease.

• Step 1 — Harvests your defensive soldiers: T-cells are collected from your blood using a specialised procedure called apheresis.
• Step 2 — Gives them a genetic radar: In a highly advanced laboratory, these cells are reprogrammed with a synthetic tracking system (a “CAR” receptor) tuned to hunt down B-cells.
• Step 3 — Deploys a precise search-and-destroy mission: Once infused back into your veins, these upgraded cells multiply rapidly and wipe out the misbehaving B-cell population.

What is the goal?

The goal is to achieve a deep immune reset by removing the B-cells driving the disease and allowing the immune system to rebuild itself over time. Researchers hope this may lead to long-lasting remission in some patients, but long-term results in myositis are still being studied.

Why is CAR T-cell therapy important in myositis?

CAR T-cell therapy is currently being investigated for patients with severe treatment-resistant myositis, disease that remains active despite steroids, Rituximab, JAK inhibitors and other advanced therapies, or significant organ involvement with ongoing disease activity.

Is CAR T-cell therapy a cure for myositis?

We do not yet know. Early studies suggest that CAR T-cell therapy may produce very deep and prolonged remissions in some autoimmune diseases. However, it is still experimental in myositis, and researchers are continuing to study its long-term effectiveness and safety.

How is CAR T-cell therapy given?

• Apheresis: blood is collected and T-cells are separated and stored.
• Cell manufacturing: cells are genetically modified in a specialised laboratory. This usually takes several weeks.
• Lymphodepletion: a short course of chemotherapy makes space for the new CAR T-cells.
• Infusion: the engineered cells are infused through a vein in a specialised hospital setting.

Unique risks that need specialised monitoring

CAR T-cell therapy is a heavy, complex procedure with unique, intense risks that require specialised ICU monitoring.

• Cytokine Release Syndrome (CRS): a massive wave of chemical alarms causing flu-like symptoms, very high fevers, and temporary blood pressure drops.
• Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS): temporary confusion, tremors, or difficulty speaking as immune activity peaks.
• Profound temporary fatigue and very low blood counts.

Why are blood tests necessary?

Intensive monitoring is required. Many tests are performed daily during the initial treatment period, including complete blood counts, liver and kidney tests, inflammatory markers (CRP, ferritin), immunoglobulin levels, and infection monitoring.

Important precautions

This is only available at select, highly specialised academic research sites, usually within experimental clinical studies.

You will need to remain in or very close to a specialised hospital centre for several weeks after the infusion to safely manage potential immune reactions.

Because B-cells may be profoundly reduced for many months, fever should be reported immediately and infection-prevention measures are essential.

Patients require monitoring for months to years after treatment.

Cost

Extremely expensive and resource-intensive. The treatment involves advanced cell manufacturing, hospitalisation, and highly specialised medical care. For most patients, access is currently through research studies or specialised clinical programmes rather than routine clinical practice.